In the end of 2020 the global supplies of the vaccine have been started.
RDIF finances the production of the Sputnik V in Russia on the basis of production capacities of its portfolio companies, R-Pharm and Binnopharm, a part of the Alium Group and start mass production in other countries in partnership with local sovereign wealth funds, including India, South Korea and Brazil, as well as, in China, Saudi Arabia and Turkey.
RDIF is conducting Phase 3 clinical trials in 4 countries: Belarus, the UAE, India and Venezuela.
The Sputnik V vaccine has already been registered in more than 65 countries, including North and South America, the Middle East, Europe, Asia and Africa.
Sputnik V has already been administered to more than 2 million people worldwide.
As of February 2021, vaccination with Sputnik V has started or is starting in more than 20 countries, including Argentina, Hungary, Bolivia, Algeria, Montenegro, Paraguay and others.
Message has been successfully sent!